SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Podcast
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
Eli Lilly becomes the latest to make a major investment in immunology and inflammation, while antibody-drug conjugate biopharma Myricx Bio nets a large Series A round and new research highlights the potential and possible risks of GLP-1s.
July 10, 2024
 · 
1 min read
 · 
Greg Slabodkin
Pictured: Amylyx co-CEOs Josh Cohen and Justin Klee
Mergers & Acquisitions
Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger
After pulling its ALS drug Relyvrio from the market, Amylyx Pharmaceuticals is looking to target the GLP-1 space with the purchase of Eiger BioPharmaceuticals’ avexitide, which has been studied for the treatment of hyperinsulinemic hypoglycemia.
July 10, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured (from left): Pfizer and Alnylam signs/Taylor Tieden for BioSpace
Cardiovascular Disease
Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data
Preliminary data from a late-stage trial of Alnylam’s RNAi therapy for ATTR amyloidosis with cardiomyopathy appear strong but details expected later this summer are critical.

July 10, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: Novo Nordisk's corporate headquarters in Denmark
Weight Loss
What Does Wegovy’s Launch in China Mean as Biosimilar Competition Emerges?
As Novo Nordisk’s weight loss drug enters the Chinese market, its patent is expiring in two years and biosimilar competition is rising.
July 9, 2024
 · 
2 min read
 · 
Tyler Patchen
Entrance of the FTC in Washington, DC
Policy
PBMs ‘Wield Enormous Power’ Over Patient Access to Affordable Drugs: FTC
The Federal Trade Commission on Tuesday issued an interim report on the top pharmacy benefit managers, showing that they are generating massive profit at the expense of patients by inflating prescription drug costs.

July 9, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A close-up of the U.S. Capitol dome/iSto
Policy
House Speaker Plans to Vote, Pass BIOSECURE Act into Law This Year
House Speaker Mike Johnson (R-La.) on Monday said he intends to have a “significant package of China-related legislation” signed into law by the end of this year, including the BIOSECURE Act which intends to stop federal contracts with Chinese “companies of concern.”

July 9, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Photo illustration of hundred dollar bil
Series A
Myricx Bio Raises $115M in Series A to Advance ADC With Lilly and Novo Backing
The U.K.-based biotech is the latest to cash in on the hot antibody-drug conjugate space, closing a $115.5 million Series A round co-led by Novo Holdings and participation from Eli Lilly.

July 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Podcasts
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
Two CRLs from the FDA last week cited concerns with third-party manufacturers, while Indian CDMOs may make a bid for U.S. business if there is a decoupling from Chinese companies under the BIOSECURE Act.
July 3, 2024
 · 
1 min read
 · 
Jef Akst
Pictured: Man climbing a DNA double helix/iStock, Moor Studio
News
Taysha Shares Positive Rett Results in Bid to Move Past Roadblocks
Taysha Gene Therapies looks to move past its pipeline culls and staff reductions by moving its lead asset into a possible billion-dollar market.
July 3, 2024
 · 
3 min read
 · 
Tyler Patchen
Biopharma items with cyber accents/Taylor Tieden for BioSpace
Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs
As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.
July 3, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Facade of Moderna's building in Massachusetts
Vaccines
Moderna to Produce Bird Flu Vaccine Under $176M BARDA Project Award
Moderna on Tuesday announced it has been awarded $176 million by a consortium funded by the Biomedical Advanced Research and Development Authority to develop an mRNA-based vaccine to counter H5N1 avian influenza.

July 2, 2024
 · 
2 min read
 · 
Tyler Patchen
FDA
FDA Approves Eli Lilly’s Donanemab to Treat Alzheimer’s Disease
Donanemab, which will be marketed as Kisunla, will compete with Biogen and Eisai’s Leqembi.
July 2, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Exterior of a Samsung location in San Jo
FDA
Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara
Pyzchiva, developed by Samsung Bioepis, will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson’s Janssen Biotech.
July 1, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Medicine vial over rock pile with comple
Drug Development
Gilead’s Trodelvy Stumbles in Late-Stage Trials But Remains Prized Cancer Asset
Gilead Sciences’ blockbuster antibody-drug conjugate Trodelvy has encountered some clinical speed bumps in 2024 in bladder and lung cancer. Still, analysts remain bullish on its prospects in the oncology space.
June 28, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: The front entrance to the FDA headquarters/iStock, Grandbrothers
Policy
FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info
Rocket Pharmaceuticals’ gene therapy Kresladi has been hit with an FDA Complete Response Letter requesting additional chemistry, manufacturing and controls information to complete its review.
June 28, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More